Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis

Trial Profile

A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Moxifloxacin (Primary) ; Pretomanid (Primary) ; Pyrazinamide (Primary) ; Isoniazid/rifampicin; Rifampicin/isoniazid/pyrazinamide/ethambutol
  • Indications Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Acronyms STAND
  • Sponsors Global Alliance for TB Drug Development
  • Most Recent Events

    • 19 Oct 2020 Status changed to discontinued as per results published in the Antimicrobial Agents and Chemotherapy.
    • 19 Oct 2020 Results of pooled data of four studies and four pretomanid-containing regimens NC-002, NC-005, STAND, and Nix-TB, retrospectively evaluating the recommended daily dose of pretomanid, 200 mg administered with food, by means of exposure-response modeling applied to outcomes of both efficacy and safety, published in the Antimicrobial Agents and Chemotherapy.
    • 29 Jul 2019 Results of quantitative modeling describing the relationship between pretomanid plasma concentrations and the change from baseline in QTc using data from eight phase 2 and phase 3 studies, published in the Antimicrobial Agents and Chemotherapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top